Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

4.07
-0.1500-3.55%
Post-market: 4.150.0800+1.97%19:55 EDT
Volume:911.28K
Turnover:3.75M
Market Cap:463.98M
PE:-2.91
High:4.23
Open:4.18
Low:4.03
Close:4.22
52wk High:6.16
52wk Low:1.60
Shares:114.00M
Float Shares:102.00M
Volume Ratio:0.34
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3971
EPS(LYR):-1.2306
ROE:-41.65%
ROA:-23.35%
PB:2.24
PE(LYR):-3.31

Loading ...

Perspective Therapeutics Announces Plans to Advance Clinical Pipeline, Expand Manufacturing Capacity, and Present Updated Data at 2026 Medical Conferences

Reuters
·
Jan 12

Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results

Reuters
·
Jan 12

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data

TIPRANKS
·
Jan 09

Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial

Reuters
·
Jan 09

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Asco Gastrointestinal Cancers Symposium

THOMSON REUTERS
·
Jan 09

Perspective Therapeutics Reports Promising [212Pb]VMT-α-NET Data in Neuroendocrine Tumor Trial

Reuters
·
Dec 04, 2025

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 28, 2025

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 26, 2025

Perspective Therapeutics Inc : Truist Securities Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Nov 24, 2025

Perspective Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Nov 22, 2025

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics price target lowered to $7 from $18 at UBS

TIPRANKS
·
Nov 21, 2025

Perspective Therapeutics to Participate in Upcoming December Conferences

GlobeNewswire
·
Nov 20, 2025

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Nov 19, 2025

B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating

MT Newswires Live
·
Nov 18, 2025

Perspective Therapeutics Chief Accounting Officer Jonathan Robert Hunt Acquires Common Shares

Reuters
·
Nov 17, 2025

Director Robert F. Williamson III Acquires Common Shares of Perspective Therapeutics Inc

Reuters
·
Nov 14, 2025

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 12, 2025

Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability

TIPRANKS
·
Nov 12, 2025

Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential

TIPRANKS
·
Nov 12, 2025